Comments

BioLine Rx Analyst Ratings

BLRXNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$3.01

-0.17-5.23%

At close: Dec 16, 4:00 PM EST

$3.10

0.092.99%

After Hours: 5:13 PM EST

Overview News Earnings Options

Analyst Ratings

Short Interest Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$26.00

Lowest Price Target¹

$4.00

Consensus Price Target¹

$14.00

BioLine Rx Analyst Ratings and Price Targets | NASDAQ:BLRX | Benzinga

BioLine Rx Ltd has a consensus price target of $14 based on the ratings of 3 analysts. The high is $26 issued by HC Wainwright & Co. on June 17, 2025. The low is $4 issued by Oppenheimer on May 25, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Jones Trading, and HC Wainwright & Co. on June 17, 2025, May 30, 2025, and May 28, 2025, respectively. With an average price target of $21.33 between HC Wainwright & Co., Jones Trading, and HC Wainwright & Co., there's an implied 588.17% upside for BioLine Rx Ltd from these most-recent analyst ratings.

Analyst Trends and Forecast

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

HC Wainwright & Co.

Jones Trading

Oppenheimer

¹calculated from analyst ratings

Analyst Ratings for BioLine Rx

					Get Alert
Jun 17, 2025	738.71%	Joseph PantginisHC Wainwright & Co. 60%	26 26	Previous Buy Current Buy	Get Alert
May 30, 2025	287.1%	Justin WalshJones Trading 54%	12	Previous Hold Current Buy	Get Alert
May 28, 2025	738.71%	Joseph PantginisHC Wainwright & Co. 60%	26 26	Previous Buy Current Buy	Get Alert
Apr 2, 2025	—	Justin WalshJones Trading 54%	—	Previous Buy Current Hold	Get Alert
Mar 31, 2025	738.71%	Joseph PantginisHC Wainwright & Co. 60%	9 26	Previous Buy Current Buy	Get Alert
Nov 25, 2024	190.32%	Joseph PantginisHC Wainwright & Co. 60%	9 21	Previous Buy Current Buy	Get Alert
Nov 6, 2024	577.42%	Joseph PantginisHC Wainwright & Co. 60%	21 21	Previous Buy Current Buy	Get Alert
Sep 4, 2024	-35.48%	Justin WalshJones Trading 54%	2	Previous Initiates Current Buy	Get Alert
Jun 3, 2024	577.42%	Joseph PantginisHC Wainwright & Co. 60%	21 21	Previous Buy Current Buy	Get Alert
May 29, 2024	577.42%	Joseph PantginisHC Wainwright & Co. 60%	21 21	Previous Buy Current Buy	Get Alert
Apr 17, 2024	577.42%	Joseph PantginisHC Wainwright & Co. 60%	21 21	Previous Buy Current Buy	Get Alert
Mar 26, 2024	577.42%	Joseph PantginisHC Wainwright & Co. 60%	21 21	Previous Buy Current Buy	Get Alert
Feb 29, 2024	577.42%	Joseph PantginisHC Wainwright & Co. 60%	21 21	Previous Buy Current Buy	Get Alert
Nov 20, 2023	577.42%	Joseph PantginisHC Wainwright & Co. 60%	21 21	Previous Buy Current Buy	Get Alert
Sep 15, 2023	577.42%	Joseph PantginisHC Wainwright & Co. 60%	19 21	Previous Buy Current Buy	Get Alert
Aug 31, 2023	512.9%	Joseph PantginisHC Wainwright & Co. 60%	19	Previous Buy Current Buy	Get Alert
May 25, 2023	29.03%	Mark BreidenbachOppenheimer 45%	4	Previous Current Outperform	Get Alert

FAQ

What is the target price for BioLine Rx (BLRX) stock?

The latest price target for BioLine Rx (NASDAQ:BLRX) was reported by HC Wainwright & Co. on June 17, 2025. The analyst firm set a price target for $26.00 expecting BLRX to rise to within 12 months (a possible 738.71% upside). 5 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for BioLine Rx (BLRX)?

The latest analyst rating for BioLine Rx (NASDAQ:BLRX) was provided by HC Wainwright & Co., and BioLine Rx reiterated their buy rating.

When was the last upgrade for BioLine Rx (BLRX)?

The last upgrade for BioLine Rx Ltd happened on May 30, 2025 when Jones Trading raised their price target to $12. Jones Trading previously had a hold for BioLine Rx Ltd.

When was the last downgrade for BioLine Rx (BLRX)?

The last downgrade for BioLine Rx Ltd happened on April 2, 2025 when Jones Trading changed their price target from N/A to N/A for BioLine Rx Ltd.

When is the next analyst rating going to be posted or updated for BioLine Rx (BLRX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLine Rx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLine Rx was filed on June 17, 2025 so you should expect the next rating to be made available sometime around June 17, 2026.

Is the Analyst Rating BioLine Rx (BLRX) correct?

While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a reiterated with a price target of $26.00 to $26.00. The current price BioLine Rx (BLRX) is trading at is $3.10, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.